50 Participants Needed

Pomalidomide + Chemotherapy for Acute Myeloid Leukemia

Recruiting at 11 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: National Cancer Institute (NCI)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, it mentions that anti-cancer therapy should be stopped more than 72 hours before starting the trial treatment, and the use of strong CYP1A2 inhibitors should be avoided. It's best to discuss your specific medications with the trial team.

What data supports the effectiveness of the drug Pomalidomide + Chemotherapy for Acute Myeloid Leukemia?

The drug CPX-351, which is part of the treatment, has shown improved outcomes in patients with acute myeloid leukemia (AML) compared to traditional chemotherapy. It has been effective in prolonging survival and achieving higher remission rates in clinical trials, particularly in older patients with high-risk AML.12345

Is the combination of Pomalidomide and CPX-351 safe for humans?

CPX-351, also known as Vyxeos, is a combination of two drugs, daunorubicin and cytarabine, used to treat certain types of acute myeloid leukemia (AML). It has been shown to have a safety profile similar to traditional chemotherapy, with some differences like more prolonged low blood cell counts. However, there is no specific safety data available for the combination of Pomalidomide with CPX-351.34678

What makes the drug Pomalidomide + Chemotherapy unique for treating Acute Myeloid Leukemia?

This drug combines Pomalidomide with a liposome-encapsulated formulation of daunorubicin and cytarabine, which maintains a specific 5:1 molar ratio to enhance effectiveness. The liposome delivery system helps protect the drugs from being broken down too quickly, allowing them to target leukemia cells more effectively and potentially reducing side effects compared to traditional chemotherapy.12346

What is the purpose of this trial?

This trial is testing if adding pomalidomide to standard chemotherapy can improve treatment for patients with a specific type of newly diagnosed leukemia. Pomalidomide works by cutting off the blood supply to cancer, boosting the immune system, and killing cancer cells. The chemotherapy drugs attack cancer cells in multiple ways. Pomalidomide is related to thalidomide and has shown remarkable activity in patients who did not respond to other treatments.

Research Team

JF

Joshua F Zeidner

Principal Investigator

Ohio State University Comprehensive Cancer Center LAO

Eligibility Criteria

Adults aged 18-75 with newly diagnosed acute myeloid leukemia (AML) and specific genetic mutations or changes related to myelodysplastic syndrome, who have good organ function and performance status. They must not have had previous AML treatment except hydroxyurea or leukapheresis, no Wilson's Disease, uncontrolled illnesses, prior allogeneic stem cell transplant, or certain cumulative doses of daunorubicin. Women of childbearing potential must test negative for pregnancy and use two forms of birth control.

Inclusion Criteria

Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 x institutional ULN
My leukemia is classified as therapy-related or stems from a previous blood disorder.
My leukemia diagnosis was confirmed with a specific test showing more than 20% immature blood cells.
See 39 more

Exclusion Criteria

Patients with psychiatric illness/social situations that would limit compliance with study requirements
My white blood cell count is high, but it can be lowered for treatment.
Patients who are receiving any other investigational agents
See 11 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Induction

Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5. In Arm A, pomalidomide is added orally once daily for 14 days starting between days 21-30.

Approximately 4-6 weeks

Consolidation

Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles.

6 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment completion, with follow-up for 30 days, then up to 5 years.

Up to 5 years

Treatment Details

Interventions

  • Liposome-encapsulated Daunorubicin-Cytarabine
  • Pomalidomide
Trial Overview The trial is testing the addition of Pomalidomide—an immunomodulatory drug—to standard chemotherapy (Daunorubicin and Cytarabine Liposome) in patients with AML that has characteristics similar to myelodysplastic syndrome. The study aims to see if this combination improves outcomes compared to the usual treatment alone.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm A (daunorubicin and cytarabine liposome, pomalidomide)Experimental Treatment4 Interventions
INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 and then pomalidomide PO QD beginning between days 21-30 for 14 days in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy and collection of blood samples throughout all phases of the trial.
Group II: Arm B (daunorubicin and cytarabine liposome)Active Control3 Interventions
INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy and collection of blood samples throughout all phases of the trial.

Liposome-encapsulated Daunorubicin-Cytarabine is already approved in United States for the following indications:

🇺🇸
Approved in United States as Vyxeos for:
  • Acute Myeloid Leukemia with myelodysplasia-related changes (AML-MRC)
  • Therapy-related AML (t-AML)

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials
14,080
Recruited
41,180,000+

Findings from Research

CPX-351, a liposomal formulation of cytarabine and daunorubicin, showed high efficacy in treating childhood acute lymphoblastic leukemia (ALL) xenograft models, achieving complete responses in four B-lineage models and a partial response in one T-lineage model.
The drug was administered at a dose that resulted in plasma drug exposures similar to those seen in patients with acute myeloid leukemia (AML), indicating its potential effectiveness and safety for use in pediatric leukemia treatment.
Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.Carol, H., Fan, MM., Harasym, TO., et al.[2021]
In a phase II study involving 125 patients with acute myeloid leukemia (AML) in first relapse, CPX-351 showed improved response rates and lower 60-day mortality in patients classified as poor-risk according to the European Prognostic Index.
While CPX-351 did not meet the overall statistical criteria for 1-year survival improvement compared to standard salvage chemotherapy, it demonstrated significant benefits in event-free survival and overall survival for the poor-risk subgroup, suggesting it may be a more effective treatment option for these patients.
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.Cortes, JE., Goldberg, SL., Feldman, EJ., et al.[2021]
VYXEOS™, a liposomal formulation of daunorubicin and cytarabine, has been shown to significantly improve overall survival and event-free survival in older patients with newly diagnosed high-risk acute myeloid leukaemia (AML) compared to conventional chemotherapy (7+3).
The treatment also resulted in higher rates of complete remission and was well-tolerated, with a safety profile similar to that of the standard chemotherapy regimen, making it a valuable option for patients with therapy-related AML or AML with myelodysplasia-related changes.
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia.Blair, HA.[2020]

References

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program. [2021]
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. [2021]
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia. [2020]
CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. [2020]
CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. [2018]
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. [2021]
Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals. [2021]
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security